R&D News | pharmaphorum

News

UK biotech ReNeuron quits AIM as financing push fails

ReNeuron has become the latest UK biotech planning to cancel its listing on the AIM exchange, saying it has been unable to raise the capital it desperately needs to keep its business afloat

News

BioMarin's change in direction claims more jobs

The sweeping changes introduced by new BioMarin chief executive Alexander Hardy continue apace, with a second round of layoffs that will cut another 225 positions from its total headcount.

News

Bayer takes lung cancer therapy hope into phase 3

Bayer has advanced its small-molecule drug BAY 2927088 into phase 3 for non-small cell lung cancer (NSCLC) with HER2 activating mutations, one of the drugs central to the company’s plan to

News

Dr Deborah Bitterfield, chief executive and founder of Lindy Biosciences

Push for self-injected drugs prompts Novartis/Lindy alliance

Novartis is putting $20 million upfront into a near-$1 billion deal with US start-up Lindy Biosciences that aims to convert biologic drugs delivered by infusion into therapies that can be s

News

Neurocrine slides as schizophrenia data disappoints

Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors.

News

Details emerge of £400m investment programme tied to VPAG

The £400 million ($529 million) investment programme pledged as part of the new voluntary system of rebates paid by pharma companies in the UK has been announced and will focus mainly on su

UK biotech ReNeuron quits AIM as financing push fails

BioMarin's change in direction claims more jobs

Bayer takes lung cancer therapy hope into phase 3

Push for self-injected drugs prompts Novartis/Lindy alliance

Neurocrine slides as schizophrenia data disappoints

Details emerge of £400m investment programme tied to VPAG

UK's Claret Capital raises €575m for European biotechs

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks